AKT1 and lung carcinoma: The combination of PI3K/AKT/mTOR and CDK4/6 inhibitors has been studied in preclinical models18,20,49 and is still under research in clinical trials in patients with advanced breast cancer (NCT02389842), lung cancer and other cancers (NCT03065062).